Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Operating activities
Net income	$ 1,997	$ 16,746
Adjustments to reconcile net income to cash used in operating activities:
Provision for bad debts	195	1,671
Deferred tax (benefit) expense	(1,596)	1,024
Depreciation and amortization	9,751	5,932
Amortization of developed technology and backlog	5,614	3,639
Amortization of debt discount and issuance costs	876	1,506
Equity-based compensation	3,941	2,798
Change in fair value of contingent consideration	(2,586)	(150)
Warranty provision	3,341	1,720
Inventory reserve	(526)	839
Other non-cash	161	0
Changes in operating assets and liabilities	(50,589)	(48,784)
Net cash used in operating activities	(29,421)	(13,059)
Investing activities
Purchase of property, plant and equipment	(7,511)	(2,352)
Net cash used in investing activities	(7,511)	(2,352)
Financing activities
Proceeds from issuance of other debt	24,218	7,862
Repayments of other debt	(27,412)	(7,294)
Repayments of term loan facility	0	(1,075)
Contingent consideration payments	(2,574)	(1,204)
Other financing	(1,844)	(14)
Net cash used in financing activities	(7,612)	(1,725)
Effect of exchange rate changes on cash and cash equivalent balances	553	2,488
Net change in cash and cash equivalents and restricted cash	(43,991)	(14,648)
Cash and cash equivalents, and restricted cash beginning of period	245,984	364,141
Cash and cash equivalents and restricted cash, end of period	$ 201,993	$ 349,493